Scheda di revisione: Sympathetic Nervous System Pharmacology

📋 Course Outline

1. Sympathetic Nervous System
2. Neurotransmitters
3. Adrenergic Receptors
4. Sympathomimetic Drugs
5. Sympatholytic Drugs
6. Pharmacological Effects
7. Clinical Indications
8. Drug Interactions

📖 1. Sympathetic Nervous System

🔑 Key Concepts & Definitions

• Sympathetic Nervous System (SNS) (source: Dr. BERERHI, 2026): A component of the autonomic nervous system responsible for regulating involuntary organ functions, especially during stress responses, by activating effector organs through specific neural pathways and mediators.

• Role in involuntary organ function regulation (source: Dr. BERERHI, 2026): The SNS modulates functions such as heart rate, vascular tone, and gland secretion, maintaining internal homeostasis and enabling rapid adaptation to stress or calm situations.

• Response to stress and calm situations (source: Dr. BERERHI, 2026): During stress, the SNS is activated, releasing mediators like noradrenaline and adrenaline to prepare the body for "fight or flight"; in calm situations, its activity diminishes, allowing parasympathetic dominance.

• Integration with central and peripheral nervous system (source: Dr. BERERHI, 2026): The SNS connects the central nervous system (brain and spinal cord) with peripheral effectors via preganglionic and postganglionic neurons, coordinating physiological responses through complex neural pathways.

• Effectors: muscles and glands (source: Dr. BERERHI, 2026): The SNS influences effectors such as smooth muscles (vascular, bronchial, urogenital) and glands (salivary, sweat, adrenal medulla) by releasing neurotransmitters that bind to adrenergic receptors, eliciting specific physiological effects.

📖 2. Neurotransmitters

🔑 Key Concepts & Definitions

• Neurotransmitters: Chemical substances released at synapses that facilitate the transmission of nerve impulses between neurons or from neurons to effector cells, as described by Dr. BERERHI (2026). They mediate communication within the nervous system, especially in the sympathetic nervous system.

• Noradrenaline and Adrenaline: Catecholamine neurotransmitters involved in the sympathetic nervous system, responsible for physiological responses such as increased heart rate, vasoconstriction, and metabolic changes. Dr. BERERHI (2026) emphasizes their role in chemical mediation at synapses and in systemic responses.

• Role of Neurotransmitters in Nerve Impulse Transmission: Neurotransmitters are released from presynaptic neurons in response to an action potential, cross the synaptic cleft, and bind to specific receptors on the postsynaptic membrane, initiating a new electrical signal or physiological response (Dr. BERERHI, 2026).

• Chemical Mediation at Synapses: The process by which neurotransmitters are released into the synaptic cleft, bind to receptors on the target cell, and are then inactivated or removed to terminate the signal, ensuring precise communication within the nervous system (Dr. BERERHI, 2026).

📝 Essential Points

• Neurotransmitters such as Noradrenaline and Adrenaline are key mediators in the sympathetic nervous system, regulating involuntary functions and stress responses (Dr. BERERHI, 2026).

• The transmission process involves release, receptor binding, and inactivation of neurotransmitters, with enzymes like MAO and COMT degrading catecholamines to terminate their action (Dr. BERERHI, 2026).

• Chemical mediation at synapses ensures rapid and targeted communication, critical for physiological responses like vasoconstriction, cardiac stimulation, and metabolic regulation (Dr. BERERHI, 2026).

💡 Key Takeaway

Neurotransmitters such as Noradrenaline and Adrenaline are essential chemical messengers in the sympathetic nervous system, mediating nerve impulse transmission and systemic physiological responses through precise chemical interactions at synapses.

📖 3. Adrenergic Receptors

🔑 Key Concepts & Definitions

• α1 adrenergic receptors (source): Located on post-synaptic cells of smooth muscles, such as those in blood vessel walls, digestive, and urogenital tracts; their activation causes contraction of these muscles, leading to vasoconstriction and other effects (source: Dr. BERERHI, 2026).

• α2 adrenergic receptors (source): Found predominantly on pre-synaptic nerve terminals; their activation inhibits norepinephrine release, reducing sympathetic activity and producing inhibitory effects (source: Dr. BERERHI, 2026).

• β1 adrenergic receptors (source): Primarily located in the heart and kidneys; stimulation increases cardiac inotropy (force of contraction), chronotropy (heart rate), and renin secretion from the kidneys (source: Dr. BERERHI, 2026).

• β2 adrenergic receptors (source): Present in smooth muscles of the bronchi, blood vessels, and urogenital tract; their activation induces muscle relaxation, leading to bronchodilation, vasodilation, and uterine relaxation (source: Dr. BERERHI, 2026).

• β3 adrenergic receptors (source): Located mainly in adipose tissue; their stimulation promotes lipolysis, breaking down fats for energy (source: Dr. BERERHI, 2026).

📝 Essential Points

• Localization and Effects of α1 Receptors: These receptors are situated on post-synaptic smooth muscle cells in vessels, digestive, and urogenital tracts. Activation causes contraction, resulting in vasoconstriction, increased blood pressure, mydriasis, and other sympathetic responses (source: Dr. BERERHI, 2026).

• Localization and Effects of α2 Receptors: Found mainly on pre-synaptic nerve terminals, where their activation inhibits norepinephrine release, thus decreasing sympathetic outflow. They also exist on some post-synaptic sites, contributing to inhibitory effects (source: Dr. BERERHI, 2026).

• Localization and Effects of β1 Receptors: Located predominantly in cardiac tissue, where their stimulation increases heart rate, contractility, and conduction velocity. They also stimulate renin release in the kidneys, influencing blood pressure regulation (source: Dr. BERERHI, 2026).

• Localization and Effects of β2 Receptors: Present in bronchial smooth muscle, vascular smooth muscle, and the urogenital tract; their activation causes relaxation of muscles, leading to bronchodilation, vasodilation, and uterine relaxation (source: Dr. BERERHI, 2026).

• Localization and Effects of β3 Receptors: Mainly in adipose tissue, where their stimulation enhances lipolysis, mobilizing fatty acids for energy production (source: Dr. BERERHI, 2026).

💡 Key Takeaway

Adrenergic receptor subtypes are strategically localized in various tissues, mediating specific physiological responses such as vasoconstriction, cardiac stimulation, bronchodilation, and lipolysis, which are crucial for the sympathetic nervous system's role in stress and homeostasis.

📖 4. Sympathomimetic Drugs

🔑 Key Concepts & Definitions

• Classification of sympathomimetic drugs: Divided into direct and indirect agents. Direct sympathomimetics activate adrenergic receptors directly, while indirect sympathomimetics increase neurotransmitter activity via release, reuptake inhibition, or degradation inhibition (Dr. BERERHI).

• Direct sympathomimetics: Drugs that bind directly to adrenergic receptors, including mixed α and β agonists, selective α agonists, and selective β agonists. They produce effects by mimicking endogenous catecholamines (Dr. BERERHI).

• Mixed α and β agonists: Agents like adrenaline, noradrenaline, and dopamine that activate both α and β adrenergic receptors, producing combined vascular, cardiac, and metabolic effects (Dr. BERERHI).

• Selective α agonists: Drugs such as phenylephrine that target α receptors specifically, mainly causing vasoconstriction and mydriasis (Dr. BERERHI).

• Selective β agonists: Drugs like salbutamol that activate β2 receptors, leading to bronchodilation and uterine relaxation (Dr. BERERHI).

• Indirect sympathomimetics: Drugs that enhance adrenergic activity by increasing neurotransmitter release (e.g., amphetamine), inhibiting reuptake (e.g., cocaine), or inhibiting degradation enzymes like MAO and COMT (Dr. BERERHI).

📝 Essential Points

• Pharmacodynamics and pharmacokinetics of catecholamines such as adrenaline, noradrenaline, and dopamine involve rapid metabolism via MAO and COMT, with very short half-lives and quick onset of action, primarily used in emergency situations (Dr. BERERHI).

• Examples and uses of α1 agonists: Phenylephrine is used for hypotension, nasal congestion, and mydriasis. It causes vasoconstriction, increasing blood pressure and reducing nasal mucosa edema (Dr. BERERHI).

• Examples and uses of β2 agonists: Salbutamol is used in asthma and preterm labor to induce bronchodilation and uterine relaxation. They act mainly on β2 receptors, causing smooth muscle relaxation (Dr. BERERHI).

• Mechanisms of indirect sympathomimetics: They increase noradrenaline levels by promoting release (amphetamines), inhibiting reuptake (cocaine), or blocking degradation (MAO inhibitors), leading to enhanced sympathetic effects (Dr. BERERHI).

• Pharmacokinetics: Adrenergic drugs are often administered parenterally due to poor oral bioavailability, rapidly metabolized, and have short durations of action, especially for adrenaline and noradrenaline (Dr. BERERHI).

💡 Key Takeaway

Sympathomimetic drugs can be classified into direct agents that activate adrenergic receptors and indirect agents that enhance endogenous neurotransmitter activity, with specific drugs tailored for cardiovascular, respiratory, and other clinical indications based on their receptor selectivity and mechanism of action.

📖 5. Sympatholytic Drugs

🔑 Key Concepts & Definitions

• Classification of sympatholytic drugs (see source): Medications that inhibit or block the sympathetic nervous system activity, divided into direct and indirect sympatholytics based on their mechanism of action.

• Direct sympatholytics (see source): Drugs that antagonize adrenergic receptors directly, including α blockers (which inhibit α-adrenergic receptors) and β blockers (which inhibit β-adrenergic receptors).

• α blockers (see source): Medications that inhibit α-adrenergic receptors. They are classified as non-selective (block both α1 and α2), α1 selective, or α2 selective (see source). Examples include phenoxybenzamine and prazosin.

• Mechanism of action of adrenergic antagonists (see source): These drugs competitively or irreversibly bind to adrenergic receptors, preventing catecholamines like noradrenaline or adrenaline from activating them, thus reducing sympathetic effects.

• Examples of α blockers (see source): Prazosin (α1 selective), phenoxybenzamine (non-selective, irreversible), used in conditions like hypertension and benign prostatic hyperplasia.

• Examples of β blockers and their cardioselectivity (see source): Drugs such as propranolol (non-selective), metoprolol (β1 selective), atenolol (β1 selective), which differ in their affinity for β1 and β2 receptors, affecting cardiac and pulmonary effects.

• Mechanism of action of indirect sympatholytics (see source): These drugs inhibit sympathetic activity by decreasing neurotransmitter synthesis (e.g., via inhibition of tyrosine hydroxylase), blocking neurotransmitter release (e.g., reserpine), or preventing neurotransmitter storage, thereby reducing catecholamine availability.

📝 Essential Points

• Sympatholytic drugs are classified as direct or indirect based on whether they block adrenergic receptors directly or inhibit neurotransmitter activity centrally or peripherally (see source).

• Direct sympatholytics include α blockers and β blockers. α blockers are used to treat hypertension and benign prostatic hyperplasia, with selectivity influencing their side effect profiles (see source). β blockers are primarily used for cardiovascular conditions such as angina, hypertension, and arrhythmias, with cardioselectivity reducing pulmonary side effects (see source).

• α blockers such as phenoxybenzamine (irreversible) and prazosin (reversible, selective α1 blocker) act by preventing catecholamine binding, leading to vasodilation and decreased blood pressure (see source). They are also utilized in managing pheochromocytoma and Raynaud's phenomenon.

• β blockers like propranolol (non-selective) and metoprolol (β1 selective) inhibit cardiac β1 receptors, decreasing heart rate and contractility, which is beneficial in ischemic heart disease and hypertension (see source). Their selectivity minimizes respiratory side effects in asthmatic patients.

• Indirect sympatholytics such as reserpine inhibit neurotransmitter storage in vesicles, leading to depletion of catecholamines, which can cause significant side effects like depression and orthostatic hypotension (see source). These are largely replaced by newer agents due to adverse effects.

• The mechanism of action of adrenergic antagonists involves competitive binding to receptors, irreversible blockade (phenoxybenzamine), or depletion of neurotransmitter stores (reserpine), resulting in diminished sympathetic tone (see source).

💡 Key Takeaway

Sympatholytic drugs modulate sympathetic activity either by directly blocking adrenergic receptors or by inhibiting neurotransmitter synthesis, release, or storage, with their selectivity and mechanism influencing their clinical applications and side effect profiles.

📖 6. Pharmacological Effects

🔑 Key Concepts & Definitions

• α1 receptor stimulation (source): Activation of α1 adrenergic receptors causes vasoconstriction and mydriasis. (source: Dr. BERERHI, 2026)
  Vasoconstriction: Constriction of blood vessels leading to increased blood pressure.
  Mydriasis: Dilation of the pupil, often used in ophthalmology.

• α2 receptor stimulation (source): Activation inhibits neurotransmitter release, primarily norepinephrine, reducing sympathetic outflow. (source: Dr. BERERHI, 2026)
  Inhibition of neurotransmitter release: Decreases sympathetic activity, leading to effects such as lowered blood pressure.

• β1 receptor stimulation (source): Activation increases cardiac inotropy (force of contraction) and chronotropy (heart rate). (source: Dr. BERERHI, 2026)
  Cardiac inotropy: Enhanced force of heart muscle contraction.
  Chronotropy: Increased heart rate.

• β2 receptor stimulation (source): Activation causes bronchodilation, vasodilation, and uterine relaxation. (source: Dr. BERERHI, 2026)
  Bronchodilation: Widening of bronchi, easing airflow.
  Vasodilation: Widening of blood vessels, reducing blood pressure.
  Uterine relaxation: Used to prevent preterm labor.

• β3 receptor stimulation (source): Activation promotes lipolysis in adipose tissue. (source: Dr. BERERHI, 2026)
  Lipolysis: Breakdown of triglycerides into free fatty acids and glycerol.

📝 Essential Points

• α1 receptor stimulation results in vasoconstriction, which increases systemic vascular resistance and blood pressure, and causes mydriasis, useful in certain clinical settings like nasal decongestion and ophthalmology.
• α2 receptor activation inhibits the release of norepinephrine at presynaptic terminals, decreasing sympathetic tone, which can lower blood pressure and reduce central nervous system excitability.
• β1 receptor stimulation enhances cardiac output by increasing heart rate and contractility, making β1 agonists valuable in treating heart failure, shock, and cardiac arrest.
• β2 receptor activation produces bronchodilation, vasodilation, and uterine relaxation, critical in managing asthma, preterm labor, and vasospastic conditions.
• β3 receptors are primarily located in adipose tissue, where their activation stimulates lipolysis, contributing to energy mobilization.

💡 Key Takeaway

Activation of specific adrenergic receptors elicits targeted pharmacological effects, such as vasoconstriction, cardiac stimulation, bronchodilation, and lipolysis, which are exploited in various clinical treatments.

📖 7. Clinical Indications

🔑 Key Concepts & Definitions

• Adrenaline (epinephrine) (source: Dr. BERERHI, 2026): A catecholamine used in emergencies such as anaphylactic shock, cardiac arrest, and severe hypotension due to its potent vasoconstrictive, bronchodilatory, and cardiac stimulating effects. It acts on α1, β1, and β2 receptors to restore circulation and airway patency.

• Noradrenaline (norepinephrine) (source: Dr. BERERHI, 2026): A primary vasopressor indicated for shock states, especially in cardiovascular collapse and severe hypotension, by predominantly stimulating α1 receptors causing vasoconstriction and increasing blood pressure; it also has β1 effects on the heart.

• Dopamine (source: Dr. BERERHI, 2026): A catecholamine used in shock and heart failure; at low doses, it stimulates dopaminergic receptors causing vasodilation, while at higher doses, it activates β1 receptors to increase cardiac output, and at very high doses, stimulates α1 receptors leading to vasoconstriction.

• α1 agonists (source: Dr. BERERHI, 2026): Drugs like phenylephrine used in hypotension, nasal congestion, and migraine; they induce vasoconstriction by stimulating α1 receptors, thus elevating blood pressure, reducing nasal mucosa edema, or alleviating migraine by vasoconstriction of cranial vessels.

• β2 agonists (source: Dr. BERERHI, 2026): Medications such as salbutamol used in asthma and preterm labor; they promote bronchodilation and uterine relaxation by stimulating β2 receptors, easing airflow and preventing premature contractions.

• α blockers (source: Dr. BERERHI, 2026): Agents like prazosin used in hypertension and benign prostatic hyperplasia; they inhibit α1 receptors, leading to vasodilation and relaxation of smooth muscles in the prostate and bladder neck, respectively.

📝 Essential Points

• Adrenaline is indicated in anaphylactic shock for its rapid bronchodilation and vasoconstriction, cardiac arrest to stimulate the heart, and hypotension in severe shock states. Its quick onset and short duration make it essential in emergency protocols.

• Noradrenaline is primarily used in shock (e.g., septic, cardiogenic) where vasoconstriction is needed to restore blood pressure, with secondary cardiac effects via β1 stimulation.

• Dopamine is versatile in shock management: low doses improve renal perfusion via dopaminergic receptors, moderate doses enhance cardiac output through β1 effects, and high doses cause vasoconstriction via α1 activation.

• α1 agonists like phenylephrine are used for hypotension (e.g., during anesthesia), nasal congestion (topical decongestants), and migraine (vasoconstriction of cranial vessels).

• β2 agonists are first-line treatments in asthma for bronchodilation and in preterm labor to relax uterine muscles, reducing the risk of premature birth.

• α blockers are used in hypertension to reduce vascular resistance and in benign prostatic hyperplasia to relieve urinary obstruction by relaxing prostatic smooth muscle.

💡 Key Takeaway

Adrenergic drugs are vital in emergency and chronic conditions involving cardiovascular, respiratory, and urological systems, with specific agents tailored to either stimulate or block adrenergic receptors to achieve therapeutic goals.

📖 8. Drug Interactions

🔑 Key Concepts & Definitions

• Interactions with MAO inhibitors, tricyclic antidepressants, and other sympathomimetics:
  These drugs can enhance the effects of sympathomimetics by inhibiting the degradation of catecholamines, leading to excessive adrenergic stimulation. BERERHI (2026): "MAO inhibitors and tricyclic antidepressants increase synaptic norepinephrine and dopamine levels, potentiating sympathomimetic effects."

• Antagonistic interactions between α and β blockers and sympathomimetics:
  When α blockers are administered with sympathomimetics, vasodilation may counteract vasoconstriction, reducing hypertensive effects. Conversely, β blockers can diminish cardiac stimulation caused by sympathomimetics, potentially leading to reduced therapeutic efficacy or adverse reactions. BERERHI (2026): "α and β blockers can antagonize sympathomimetic actions, affecting blood pressure and heart rate regulation."

• Interactions affecting insulin and blood glucose levels:
  Sympathomimetics, especially β2 agonists, can induce hyperglycemia by stimulating glycogenolysis and lipolysis, which may interfere with insulin therapy. BERERHI (2026): "β2 adrenergic stimulation increases blood glucose, potentially requiring insulin dose adjustments."

• Potentiation or inhibition with other cardiovascular drugs:
  Sympathomimetics can potentiate the hypertensive and tachycardic effects of other cardiovascular agents, while β blockers may inhibit these effects, impacting blood pressure control and cardiac workload. BERERHI (2026): "Interactions between sympathomimetics and cardiovascular drugs can alter therapeutic outcomes, necessitating careful monitoring."

• Interactions leading to adverse effects or contraindications:
  Combining sympathomimetics with certain drugs (e.g., MAO inhibitors, tricyclic antidepressants) can cause hypertensive crises, arrhythmias, or severe vasoconstriction. These combinations are contraindicated or require caution. BERERHI (2026): "Drug interactions may precipitate life-threatening adverse effects, especially with monoamine oxidase inhibitors and certain antidepressants."

📝 Essential Points

• Sympathomimetics' effects are significantly amplified when combined with MAO inhibitors or tricyclic antidepressants due to decreased catecholamine degradation (BERERHI, 2026).
• Antagonistic interactions occur when α or β blockers are used with sympathomimetics, potentially reducing their efficacy or causing unpredictable blood pressure and heart rate responses (BERERHI, 2026).
• Blood glucose levels can be affected by sympathomimetics, especially β2 agonists, which may induce hyperglycemia and complicate diabetic management (BERERHI, 2026).
• Combining sympathomimetics with other cardiovascular drugs can lead to potentiation of hypertensive or arrhythmic effects, requiring careful dose adjustments and monitoring (BERERHI, 2026).
• Certain drug combinations are contraindicated due to risk of hypertensive crises, arrhythmias, or ischemia, notably with MAO inhibitors and tricyclic antidepressants (BERERHI, 2026).

💡 Key Takeaway

Drug interactions with sympathomimetics can significantly alter their effects, sometimes leading to dangerous adverse reactions; therefore, careful consideration and monitoring are essential when these drugs are combined with other medications.

📅 Key Dates

(OMITTED: No significant dates or chronological events provided in the content)

📊 Synthesis Tables

Receptor Type	Location	Main Effects	Activation Effects	Authors / References
α1	Post-synaptic smooth muscles (vessels, GI, urogenital)	Contraction, vasoconstriction	Vasoconstriction, mydriasis, increased blood pressure	Dr. BERERHI, 2026
α2	Pre-synaptic nerve terminals	Inhibition of norepinephrine release	Decreased sympathetic activity, inhibitory effects	Dr. BERERHI, 2026
β1	Heart, kidneys	Increased heart rate, contractility, renin secretion	Cardiac stimulation, increased BP	Dr. BERERHI, 2026
β2	Bronchi, blood vessels, urogenital tract	Relaxation of smooth muscles	Bronchodilation, vasodilation, uterine relaxation	Dr. BERERHI, 2026
β3	Adipose tissue	Lipolysis	Fat breakdown for energy	Dr. BERERHI, 2026

Drug Type	Mechanism	Effects	Examples	Authors / References
Direct	Bind directly to adrenergic receptors	Mimic endogenous catecholamines	Adrenaline, noradrenaline, phenylephrine, salbutamol	Dr. BERERHI, 2026
Indirect	Increase neurotransmitter activity via release, reuptake inhibition, or degradation inhibition	Enhance sympathetic responses	Amphetamines, cocaine	Dr. BERERHI, 2026

⚠️ Common Pitfalls & Confusions

1. Confusing α1 and α2 receptor locations and effects; α1 causes contraction, α2 inhibits neurotransmitter release.
2. Misidentifying the primary effects of β2 receptors as solely cardiac; they are mainly in bronchial and vascular smooth muscle causing relaxation.
3. Assuming all adrenergic drugs are non-selective; many are selective for α or β subtypes.
4. Overlooking the role of enzymes like MAO and COMT in catecholamine inactivation.
5. Confusing sympathomimetic drugs with sympatholytic drugs; the latter inhibit sympathetic activity.
6. Misunderstanding the difference between direct and indirect sympathomimetics in mechanism of action.
7. Ignoring the clinical relevance of receptor localization when predicting drug effects.

✅ Exam Checklist

• Know the definition and role of the Sympathetic Nervous System as described by Dr. BERERHI (2026).
• Understand the process of neurotransmitter release, action, and inactivation, especially the roles of noradrenaline and adrenaline.
• Be able to identify the locations and effects of α1, α2, β1, β2, and β3 adrenergic receptors, including their physiological responses.
• Differentiate between direct and indirect sympathomimetic drugs, with examples such as adrenaline, noradrenaline, phenylephrine, and salbutamol.
• Know the pharmacological effects of adrenergic receptor activation on organs like the heart, blood vessels, bronchi, and adipose tissue.
• Recognize the clinical indications for sympathomimetic drugs, including their use in shock, asthma, and nasal congestion.
• Understand the mechanisms of action of sympatholytic drugs and their therapeutic applications.
• Be familiar with drug interactions involving adrenergic drugs, including contraindications and caution with MAO inhibitors.
• Know key authors and references, especially Dr. BERERHI (2026), for definitions and core concepts.
• Comprehend the systemic responses mediated by neurotransmitters and adrenergic receptors during stress and relaxation.
• Understand the effects of drugs on adrenergic receptors and their clinical implications.
• Recall the processes of chemical mediation at synapses, including release, receptor binding, and degradation.